JP2024513247A5 - - Google Patents
Info
- Publication number
- JP2024513247A5 JP2024513247A5 JP2023561333A JP2023561333A JP2024513247A5 JP 2024513247 A5 JP2024513247 A5 JP 2024513247A5 JP 2023561333 A JP2023561333 A JP 2023561333A JP 2023561333 A JP2023561333 A JP 2023561333A JP 2024513247 A5 JP2024513247 A5 JP 2024513247A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cancer
- pembrolizumab
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163172299P | 2021-04-08 | 2021-04-08 | |
| US63/172,299 | 2021-04-08 | ||
| PCT/US2022/023250 WO2022216580A1 (en) | 2021-04-08 | 2022-04-04 | Methods for treating cancer with subcutaneous administration of anti-pd1 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024513247A JP2024513247A (ja) | 2024-03-22 |
| JP2024513247A5 true JP2024513247A5 (cg-RX-API-DMAC7.html) | 2024-05-28 |
Family
ID=83546458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023561333A Pending JP2024513247A (ja) | 2021-04-08 | 2022-04-04 | 抗pd-1抗体の皮下投与によるがんの治療方法 |
Country Status (21)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112203642B (zh) | 2019-03-25 | 2025-03-07 | 阿特根公司 | 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物 |
| WO2025140467A1 (zh) * | 2023-12-29 | 2025-07-03 | 上海复宏汉霖生物技术股份有限公司 | 稳定的高浓度抗pd-1抗体药物制剂 |
| WO2026124472A1 (zh) * | 2024-12-10 | 2026-06-18 | 四川科伦博泰生物医药股份有限公司 | 治疗组合及其用途和治疗方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| EP2330213A1 (en) | 2003-03-05 | 2011-06-08 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| WO2014165422A1 (en) | 2013-04-02 | 2014-10-09 | Merck Sharp & Dohme Corp. | Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| EP3634484A4 (en) * | 2017-06-05 | 2022-01-12 | The Council of the Queensland Institute of Medical Research | A COMBINATION OF OR A BI-SPECIFIC BINDING MOLECULE TO AN IMMUNOCONTROL MOLECULE ANTAGONIST AND A RANK-L (NF-κB-LIGAND) ANTAGONIST FOR CANCER THERAPY OR PROPHYLAXIS AND USES THEREOF |
| CN119792515A (zh) * | 2018-02-13 | 2025-04-11 | 默沙东有限责任公司 | 用抗pd-1抗体和抗ctla-4抗体治疗癌症的方法 |
| MX2020009824A (es) | 2018-07-25 | 2021-01-15 | Alteogen Inc | Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma. |
| US20210380694A1 (en) * | 2018-11-07 | 2021-12-09 | Merck Sharp & Dohme Corp. | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
| CN112203642B (zh) * | 2019-03-25 | 2025-03-07 | 阿特根公司 | 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物 |
-
2022
- 2022-04-01 TW TW111112795A patent/TW202305009A/zh unknown
- 2022-04-04 CR CR20230473A patent/CR20230473A/es unknown
- 2022-04-04 CA CA3214617A patent/CA3214617A1/en active Pending
- 2022-04-04 CN CN202280033638.8A patent/CN117279952A/zh active Pending
- 2022-04-04 US US18/554,213 patent/US20250074983A1/en active Pending
- 2022-04-04 IL IL307430A patent/IL307430A/en unknown
- 2022-04-04 EP EP22785209.2A patent/EP4320163A4/en active Pending
- 2022-04-04 KR KR1020237038583A patent/KR20230170029A/ko active Pending
- 2022-04-04 JP JP2023561333A patent/JP2024513247A/ja active Pending
- 2022-04-04 WO PCT/US2022/023250 patent/WO2022216580A1/en not_active Ceased
- 2022-04-04 AR ARP220100836A patent/AR125296A1/es unknown
- 2022-04-04 PE PE2023002821A patent/PE20240051A1/es unknown
- 2022-04-04 MX MX2023011857A patent/MX2023011857A/es unknown
- 2022-04-04 GE GEAP202416385A patent/GEAP202416385A/en unknown
- 2022-04-04 AU AU2022254960A patent/AU2022254960A1/en active Pending
- 2022-04-04 BR BR112023020867A patent/BR112023020867A2/pt not_active Application Discontinuation
-
2023
- 2023-10-04 CL CL2023002976A patent/CL2023002976A1/es unknown
- 2023-10-05 DO DO2023000216A patent/DOP2023000216A/es unknown
- 2023-10-05 CO CONC2023/0013273A patent/CO2023013273A2/es unknown
- 2023-10-06 EC ECSENADI202376276A patent/ECSP23076276A/es unknown
- 2023-10-08 JO JOJO/P/2023/0243A patent/JOP20230243A1/ar unknown
-
2026
- 2026-04-21 DO DO2026000117A patent/DOP2026000117A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kim et al. | Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer | |
| JP5765634B2 (ja) | 低酸素活性化型プロドラッグを用いるがんの処置 | |
| JP2019532051A5 (cg-RX-API-DMAC7.html) | ||
| EP3524268A1 (en) | Use of combination of anti-pd-1 antibody and vegfr inhibitor in preparation of drug for treating cancers | |
| JP2019517549A5 (cg-RX-API-DMAC7.html) | ||
| JP2011511072A5 (cg-RX-API-DMAC7.html) | ||
| JP2012506448A5 (cg-RX-API-DMAC7.html) | ||
| US9205098B2 (en) | Anti-cancer therapies | |
| JP2021520406A5 (cg-RX-API-DMAC7.html) | ||
| JP2020505425A5 (cg-RX-API-DMAC7.html) | ||
| RU2018126829A (ru) | Применение производных хинолина для лечения рака пищевода, а также способ лечения, фармацевтическая композиция и набор с их использованием | |
| JP2025504278A5 (cg-RX-API-DMAC7.html) | ||
| JP2023539589A5 (cg-RX-API-DMAC7.html) | ||
| JP2022527334A5 (cg-RX-API-DMAC7.html) | ||
| IL307430A (en) | Methods for treating cancer with subcutaneous administration of ANTI-PD1 antibodies | |
| JP2024524461A5 (cg-RX-API-DMAC7.html) | ||
| JP2019038797A5 (cg-RX-API-DMAC7.html) | ||
| JP2024515879A5 (cg-RX-API-DMAC7.html) | ||
| Nie et al. | An exploration of Trifluridine/Tipiracil monotherapy and in combination with bevacizumab or immune checkpoint inhibitors for patients with metastatic colorectal cancer: A Real-World study | |
| JP2021523096A5 (cg-RX-API-DMAC7.html) | ||
| TWI598095B (zh) | 治療或緩解高齡或末期癌症患者用之醫藥組合物 | |
| JP2023531090A5 (cg-RX-API-DMAC7.html) | ||
| JP2005508323A5 (cg-RX-API-DMAC7.html) | ||
| EP3127544B1 (en) | Anti-tumor drug containing anti-tumor platinum complex, and anti-tumor effect enhancer | |
| Turkington et al. | A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma |